Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (9065)	9/28/2000 1:09:44 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 9262

I agree. However, it's still possible to have a great "hunker down" portfolio in biotech. The liquidity that has hit the sector is a monstrous flood, and it's not slowing. We've never seen anything like this. The "trickle down" portfolios will be hitting the airwaves soon. Money will be looking for a safe, leveraged home. It's going to find microcap biotechs and biotech "tool companies". NBSC fits both bills, IMO. But, please remember.... someone who has been executing through Herzog et al. has been knocking it back for some time. Looks like capping, not buying, to me. I don't understand the intent, as DGI is private.